Personal profile
Personal webpage
https://www.kuball-laboratories.com/jurgen-kuball
http://nl.linkedin.com/pub/jurgen-kuball/88/156/49b
Biography
Prof. Dr. Jürgen Kuball is Chair of the Department of Hematology, and Director of the Bone Marrow Transplantation Program at the UMC Utrecht Cancer Centre. His research activities focus on tumor immunology and the ATMP development of a next generation of engineered immune cells, with an emphasis on the therapeutic potential of individual receptors derived from γδT cells. His clinical activities focus around acute leukemia and allogeneic stem cell transplantation. He is an active member of European Society for Blood and Marrow Transplantation (EBMT), and has chaired the Legal Regulatory Affairs Committee of the EBMT since 2019.
Dr. Kuball received his medical degree in Hematology at the University of Mainz, Germany, and completed his post-doctoral fellowship at the Fred Hutchinson Cancer Center in Seattle, WA, USA. He joined the Department of Hematology at the UMC Utrecht in 2007 as a hematologist and immunologist. In 2010, he became a VIDI-laureate, and the chair of the Applied & Tumor-Immunology section within the Laboratory of Translation Immunology. He has chaired the Department of Hematology (adults) since 2013.
For more information on experimental and translational research please visit Kuball Laboratories
Fellowship & awards
American Association of Cancer Research-GlaxoSmithKline Scholar in Cancer Research Award (2001)
Stipendiat der Deutschen Krebshilfe (2005-2007)
Team Science recognition award of the „Society for Immunotherapy of Cancer“ to Jürgen Kuball and the University of Washington, USA (2010)
VIDI-Laureate ZonMW, The Netherlands (2010)
External positions
aandeelhouder - shareholder via Gadeta Founders - Century Therapeutics & Adeta
1 Jan 2024 → 31 Dec 3999
Chair - Chairing - Immunology Community Life Science
1 Jan 2023 → 31 Dec 3999
Secretary team member - bestuurslid - GoCART Coalition (EBMT/EHA)
1 Jan 2023 → 31 Dec 3999
Inkomsten licentie - Onderzoek - UMCU Holding
1 Jan 2022 → 31 Dec 3999
Commissie lid PPS commissie - grant indieningen voor KWF beoordelen - KWF
1 Jan 2022 → 31 Dec 3999
aandeelhouder - Receiving revenues from licensed patents via UMCU - UMC Holding
1 Jan 2021 → 31 Dec 3999
Chair legal and rgulatory affairs committee - Chair - EBMT
1 Jan 2019 → 31 Dec 3999
grant - grant ontvangen voor onderzoek - Novartis
1 Jan 2015 → 31 Dec 3999
Onderzoeker - grant ontvangen voor onderzoek - Miltenyi
1 Jan 2015 → 31 Dec 3999
bestuurslid - member general Board - HOVON
1 Jan 2014 → 31 Dec 3999
Patent holder multipe inventions licensed to Gadeta-follow up company Century Therapeuitcs &Miltenyi - Patent houder - Various
1 Jan 2013 → 31 Dec 3999
Collaborations and top research areas from the last five years
-
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma
Rade, M., Fandrei, D., Kreuz, M., Seiffert, S., Grahnert, A., Friedrich, M., Wiemers, T., Born, P., Fischer, L., Weidner, H., Hofbauer, L. C., Baber, R., Wang, S. Y., Bach, E., Hoffmann, S., Scolnick, J., Friedrich, M., Keramati, F., Brazda, P. & Sebestyen, Z. & 16 others, , 9 Mar 2026, In: Cancer Cell. 44, 3, p. 586-603.e9Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Author Correction: Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
Kimman, T., Cuenca, M., Tieland, R. G., Rockx-Brouwer, D., Janssen, J., Motais, B., Slomp, A., Pleijte, C., Heijhuurs, S., Meringa, A. D., Boschloo, W., Bosma, D. M. T., Kroos, S., Lo Presti, V., Sluijter, J. P. G., Nierkens, S., Bovenschen, N., Kuball, J., van Mil, A. & Minnema, M. C. & 2 others, , 13 Apr 2026, In: Nature Communications. 17, 1, 3442.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Open AccessFile -
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe
Ammar, D., Sanges, C., Henderson, D., Schapitz, I., Hudecek, M., Luu, M., Schüssler-Lenz, M., Buchholz, C., Franz, P., Reiche, K., Köhl, U., Ifrah, N., Quesnel, B., Thermeli, M., Kersten, M. J., Locatelli, F., D'Amore, M. L., Bonini, C., Casucci, M. & Philippar, U. & 20 others, , Jan 2026, In: Cytotherapy. 28, 1, 101984.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Cis- and trans-binding chimeric costimulatory receptors enhance T-cell fitness and tumor control
Hernández-López, P., Riillo, C., Gasull-Celades, L., Lommen, J. G. E., Heijhuurs, S., Zheng, J., van Bruggen, S., Zintchenko, M., Brandl, S. M., Minguet, S., Kuball, J. & Beringer, D. X., Jan 2026, In: Cellular and Molecular Immunology. 23, 1, p. 79-93 15 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer"
de Bont, D. A., Straetemans, T., Sebestyén, Z. & Kuball, J., 24 Feb 2026, In: Journal for immunotherapy of cancer. 14, 2Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure)
Activities
-
Antibody Engineering and Therapeutics Europe
Leusen, J. (Keynote/plenary speaker) & Kuball, J. (Invited speaker)
10 Jun 2020 → 11 Jun 2020Activity: Participating in or organising an event › Participation in conference › Academic
-
Bureaucratische regels en te weinig geld: Jaagt Nederland toponderzoek het land uit?
Clevers, H. (Interviewee), Fuchs, S. A. (Interviewee), Kuball, J. (Interviewee) & Bredenoord, A. L. (Interviewee)
9 Mar 2020Activity: Other › Types of Public engagement and outreach - Media article or participation